You are here: Industry Insights > Cell Therapy

News List

Bayer acquires BlueRock Therapeutics to build leading position in cell therapy biospectrumasia
August 15, 2019
Implied total company value of up to $1 billion, inclusive of 40.8 percent stake currently held by Bayer / Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year / BlueRo
ReNeuron climbs on updated vision loss cell therapy data fiercebiotech
April 28, 2019
ReNeuron has reported further improvements in the vision of patients treated with its cell therapy. The mean increase in visual acuity across the three retinitis pigmentosa (RP) patients now stands at 23 letters, well above the level deemed clinically mea
Precigen Opens Cell Therapy Mfg. Facility in MD contractpharma
April 28, 2019
Precigen, Inc., a wholly-owned subsidiary of Intrexon Corp. and a clinical stage biopharmaceutical company specializing in the development of gene and cellular therapies has opened its new manufacturing facility in Germantown, MD.
Orgenesis, ExcellaBio Enter Cell Therapy Tie-up contractpharma
April 18, 2019
Orgenesis, a developer, manufacturer and service provider of advanced cell therapies, has entered into a collaboration and licensing agreement with ...
Immatics, Roche ally to trial Tecentriq with cell therapy fiercebiotech
February 27, 2019
Immatics has struck a deal to test its autologous cell therapy in combination with Roche’s checkpoint inhibitor Tecentriq. The clinical collaboration clears Immatics to test whether Roche’s antibody boosts the efficacy of its IMA101 in solid tumors....
Cell therapy produces encouraging first results in eye trial pharmaphorum
February 26, 2019
UK-based biotech ReNeuron has announced encouraging results from an early stage trial of its cell therapy for the rare blindness-causing disease, retinitis pigmentosa (RP).
Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies pharmafocusasia
January 21, 2019
Obsidian Therapeutics, a biotechnology company developing cell therapies with pharmacologic operating systems, today announced a strategic collaboration with ....
Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH fiercebiotech
January 03, 2019
Shares of cell therapy developer Fate Therapeutics shot up more than 8% Friday morning to $15.31 after the company announced that the FDA accepted its IND application for a ......
Intellia Therapeutics and Novartis Expand Cell Therapy Collaboration to Pursue CRISPR/Cas9-based Genome Editing in Additional Stem Cell Population americanpharmaceuticalreview
December 10, 2018
Intellia Therapeutics, Inc., a genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo.....
Oxford BioMedica unveils digital initiative to streamline manufacturing pharmatimes
November 26, 2018
UK gene and cell therapy group Oxford BioMedica has announced a new digital framework initiative to streamline the production of next-generation medicines.

Previous page 1 2 3 4 5 6 7 8 Next page